Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (321-330 of 348) with videos related to

Pageof 35
Sort By:
Nature Medicine|May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaDavid A Braun, Yue Hou, Ziad Bakouny, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2023
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse modelsMeenal Datta, Sampurna Chatterjee, Elizabeth M Perez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in GlioblastomaJ Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, et al.
Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trialNourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Molecular Cancer|March 16, 2024
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effectsYufei Wang, Alicia Buck, Brandon Piel, et al.
Cancer Discovery|February 16, 2021
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint BlockadeShengqing Stan Gu, Wubing Zhang, Xiaoqing Wang, et al.
Cancer Discovery|June 28, 2017
Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma TransitionCarlos R Gil Del Alcazar, Sung Jin Huh, Muhammad B Ekram, et al.
Pageof 35

Showing results (321-330 of 348) with videos related to

Sort By:
Pageof 35
Nature Medicine|May 31, 2020
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaDavid A Braun, Yue Hou, Ziad Bakouny, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2023
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse modelsMeenal Datta, Sampurna Chatterjee, Elizabeth M Perez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in GlioblastomaJ Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, et al.
Cancer Discovery|October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsEsra A Akbay, Shohei Koyama, Julian Carretero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trialNourhan El Ahmar, Morgan A Paul, Berkay Simsek, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Molecular Cancer|March 16, 2024
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effectsYufei Wang, Alicia Buck, Brandon Piel, et al.
Cancer Discovery|February 16, 2021
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint BlockadeShengqing Stan Gu, Wubing Zhang, Xiaoqing Wang, et al.
Cancer Discovery|June 28, 2017
Immune Escape in Breast Cancer During <i>In Situ</i> to Invasive Carcinoma TransitionCarlos R Gil Del Alcazar, Sung Jin Huh, Muhammad B Ekram, et al.
Pageof 35